Original Publication Date: >30 October, 2015
Publication / Source: Neurodegenerative Disease Management
Authors: Jennifer G Goldman, Neelum T Aggarwal & Cynthia D Schroeder
Cognitive dysfunction is an important focus of research in Parkinson’s disease (PD) and Alzheimer’s disease (AD). While the concept of amnestic mild cognitive impairment (MCI) as a prodrome to AD has been recognized for many years, the construct of MCI in PD is a relative newcomer with recent development of diagnostic criteria, biomarker research programs and treatment trials. Controversies and challenges, however, regarding PD-MCI’s definition, application, heterogeneity and different trajectories have arisen.